Markets›CMMB

Chemomab Therapeutics Ltd.

CMMB
1.64
-0.52 (-24.07%)
Closing price for Sep 28, 2026 from Polygon.io

Key statistics

Previous close2.16
Open2.20
Day's range1.61 to 2.22
52-week range1.35 to 3.58
Volume349.8K
Average volume (3 months)166.8K
1-year price change-38.11%
Market value11.88M
Beta (1 year)1.78
Dividend yieldNone

Company figures come from SEC filings through the quarter ending Jun 30, 2025. All statistics

About Chemomab Therapeutics Ltd.

Full profile

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Industry: Pharmaceutical Preparations · Employees: 12 · Headquarters: TEL AVIV, L3

For learning only, not investment advice. Chart by TradingView. How to read a stock quote.